These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33316742)

  • 41. Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
    Cavallini C; Galasso M; Pozza ED; Chignola R; Lovato O; Dando I; Romanelli MG; Krampera M; Pizzolo G; Donadelli M; Scupoli MT
    Br J Haematol; 2021 Jan; 192(2):333-342. PubMed ID: 33216963
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
    Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M
    Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
    Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia.
    Scrivener S; Goddard RV; Kaminski ER; Prentice AG
    Leuk Lymphoma; 2003 Mar; 44(3):383-9. PubMed ID: 12688308
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia.
    O'Brien S; Osterborg A
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):361-8. PubMed ID: 21030349
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.
    Klepfish A; Gilles L; Ioannis K; Rachmilewitz EA; Schattner A
    Ann N Y Acad Sci; 2009 Sep; 1173():865-73. PubMed ID: 19758239
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chicken-derived CD20 antibodies with potent B-cell depletion activity.
    Chockalingam K; Kumar A; Song J; Chen Z
    Br J Haematol; 2022 Nov; 199(4):560-571. PubMed ID: 36039695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism.
    Pedersen IM; Buhl AM; Klausen P; Geisler CH; Jurlander J
    Blood; 2002 Feb; 99(4):1314-9. PubMed ID: 11830481
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
    Buchner M; Brantner P; Stickel N; Prinz G; Burger M; Bär C; Dierks C; Pfeifer D; Ott A; Mertelsmann R; Gribben JG; Veelken H; Zirlik K
    Br J Haematol; 2010 Oct; 151(2):167-78. PubMed ID: 20738306
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
    Zent CS; Taylor RP; Lindorfer MA; Beum PV; LaPlant B; Wu W; Call TG; Bowen DA; Conte MJ; Frederick LA; Link BK; Blackwell SE; Veeramani S; Baig NA; Viswanatha DS; Weiner GJ; Witzig TE
    Am J Hematol; 2014 Jul; 89(7):757-65. PubMed ID: 24723493
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.
    Byrd JC; Kitada S; Flinn IW; Aron JL; Pearson M; Lucas D; Reed JC
    Blood; 2002 Feb; 99(3):1038-43. PubMed ID: 11807010
    [TBL] [Abstract][Full Text] [Related]  

  • 52. STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia.
    Debant M; Burgos M; Hemon P; Buscaglia P; Fali T; Melayah S; Le Goux N; Vandier C; Potier-Cartereau M; Pers JO; Tempescul A; Berthou C; Bagacean C; Mignen O; Renaudineau Y
    J Immunother Cancer; 2019 Apr; 7(1):111. PubMed ID: 31014395
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.
    Pickartz T; Ringel F; Wedde M; Renz H; Klein A; von Neuhoff N; Dreger P; Kreuzer KA; Schmidt CA; Srock S; Schoeler D; Schriever F
    Exp Hematol; 2001 Dec; 29(12):1410-6. PubMed ID: 11750099
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.
    Iida S; Kuni-Kamochi R; Mori K; Misaka H; Inoue M; Okazaki A; Shitara K; Satoh M
    BMC Cancer; 2009 Feb; 9():58. PubMed ID: 19226457
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is there a role for anti-CD20 antibodies in CLL?
    Shah HR; Stephens DM
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):68-75. PubMed ID: 34889417
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.
    Rafiq S; Butchar JP; Cheney C; Mo X; Trotta R; Caligiuri M; Jarjoura D; Tridandapani S; Muthusamy N; Byrd JC
    J Immunol; 2013 Mar; 190(6):2702-11. PubMed ID: 23418626
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rituximab in chronic lymphocytic leukemia.
    Jaglowski SM; Byrd JC
    Semin Hematol; 2010 Apr; 47(2):156-69. PubMed ID: 20350663
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell malignancies.
    Stasiłojć G; Felberg A; Urban A; Kowalska D; Ma S; Blom AM; Lundin J; Österborg A; Okrój M
    J Immunol Methods; 2020 Jan; 476():112675. PubMed ID: 31629742
    [TBL] [Abstract][Full Text] [Related]  

  • 60. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.